Andrew Combs
2021
In 2021, Andrew Combs earned a total compensation of $2.6M as EVP and Head of Chemistry at Prelude Therapeutics, a 31% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $156,000 |
|---|---|
| Option Awards | $2,068,828 |
| Salary | $406,461 |
| Total | $2,631,289 |
Combs received $2.1M in option awards, accounting for 79% of the total pay in 2021.
Combs also received $156K in non-equity incentive plan and $406.5K in salary.
Rankings
In 2021, Andrew Combs' compensation ranked 4,953rd out of 12,415 executives tracked by ExecPay. In other words, Combs earned more than 60.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,953 out of 12,415 | 60th |
Division Manufacturing | 2,079 out of 5,508 | 62nd |
Major group Chemicals And Allied Products | 887 out of 2,378 | 63rd |
Industry group Drugs | 794 out of 2,099 | 62nd |
Industry Pharmaceutical Preparations | 566 out of 1,549 | 64th |
Source: SEC filing on April 29, 2022.
Combs' colleagues
We found three more compensation records of executives who worked with Andrew Combs at Prelude Therapeutics in 2021.